Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.

“As we await Biomedical Advanced Research and Development Authority (BARDA) and other federal and state non-dilutive grant decisions, we expect to use our available cash to continue development of TerraCoV2, with the goal of bringing this COVID-19 vaccine candidate into human clinical trials by early 2021,” said Alan Joslyn, Ph.D., president and CEO of Oragenics.

Learn more about Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program.